PolyPid Q2 Earnings Call Highlights

1 hour ago 2

MarketBeat

Wed, August 12, 2026 astatine 11:04 AM CDT 6 min read

Key Points

Interested successful PolyPid Ltd.? Here are 5 stocks we similar better.
FDA reappraisal advances: PolyPid's NDA for D-PLEX100 was accepted connected July 27, 2026, with precedence reappraisal and a Nov. 28 PDUFA people date. The institution is preparing for a pre-approval manufacturing inspection.
Azurity concern provides backing and commercialization support: The U.S. and Canada statement includes $30 cardinal successful upfront and near-term milestone payments, much than $290 cardinal successful imaginable further milestones, and tiered royalties. Azurity expects to motorboat D-PLEX100 successful aboriginal 2027 if approved.
Financial presumption improved: PolyPid's second-quarter nett nonaccomplishment narrowed to $7.8 cardinal from $10 cardinal a twelvemonth earlier, portion the consequent Azurity payments strengthened liquidity and are expected to money operations into 2028.

PolyPid (NASDAQ:PYPD) said its second-quarter 2026 was marked by the FDA's acceptance of its caller cause exertion for D-PLEX100 and a commercialization statement with Azurity Pharmaceuticals covering the United States and Canada.

D-PLEX100 is being developed to forestall surgical tract infections successful patients undergoing abdominal corrective surgery. CEO Dikla Czaczkes Akselbrad said the FDA accepted the company's NDA for filing connected July 27, aft the institution completed its submission during the 2nd quarter. The bureau granted precedence reappraisal and acceptable a Prescription Drug User Fee Act extremity day of Nov. 28, 2026.

→ SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat

Akselbrad said the FDA identified nary filing reappraisal issues successful the acceptance notice. Priority reappraisal reduces the modular reappraisal timeline to six months from 10 months, according to the company. PolyPid expects an FDA pre-approval inspection of its manufacturing installation arsenic portion of the reappraisal process and continues to hole for that inspection done mock audits and extracurricular consultants.

Azurity Partnership Adds Upfront Payments and Potential Milestones

On July 17, PolyPid entered an exclusive statement with Azurity Pharmaceuticals to commercialize D-PLEX100 successful the U.S. and Canada. PolyPid said it has secured $30 cardinal successful aggregate upfront and near-term milestone payments, consisting of a $15 cardinal outgo astatine signing and a further $15 cardinal outgo pursuing FDA acceptance of the NDA.

→ AST SpaceMobile Earnings Just Reminded Investors How Risky Space Can Be

The statement besides provides PolyPid eligibility for much than $290 cardinal successful further regulatory, motorboat and income milestones. The institution is entitled to tiered royalties connected Azurity's nett income ranging from the mid-teens to mid-20s percentages. PolyPid volition clasp planetary manufacturing work and volition person an agreed transportation terms for each portion supplied to Azurity.

Read Entire Article